Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01458054 · ClinicalTrials.gov registry record · Phase 1
Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT01458054 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 28 participants.
The verdict
NCT01458054, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study is a Phase I open label drug interaction study to evaluate the effect of omeprazole and ritonavir on GSK2336805.
Interventions
- DRUG Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose)
- DRUG Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-09-27 |
| Est. Completion | 2011-11-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01458054
The ClinicalTrials.gov registry entry for NCT01458054 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose) is the first listed.
NCT01458054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01458054 about?
NCT01458054 is a clinical study titled "Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults". This study is a Phase I open label drug interaction study to evaluate the effect of omeprazole and ritonavir on GSK2336805.
What is the current status of trial NCT01458054?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2011-09-27. Estimated completion is 2011-11-28.
What interventions are being tested in trial NCT01458054?
The interventions under investigation include: Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose) (DRUG), Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose) (DRUG).
Who is sponsoring clinical trial NCT01458054?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.